Globus Medical Announces Completion of Synaptive Acquisition After Deal Closed in August
Key Facts
Globus Medical said on November 3, 2026, that it had completed its acquisition of Synaptive Medical, a move it said deepens its presence in cranial neurosurgery and gives it growth opportunities in the market. The deal actually closed on August 4, 2026, through court-appointed receivership proceedings. The company said the acquisition adds technologies that support neurosurgery to its portfolio. The completion announcement comes about three months after the deal’s closing date. The company did not disclose the acquisition price in its statement.
Synaptive develops technologies for complex cranial procedures, including surgical imaging, navigation, surgical planning and magnetic resonance imaging. Globus Medical Chief Executive Keith Pfeil said the acquired company brings proven surgical planning and imaging technologies, as well as relationships with leading neurosurgery centers. The addition reflects Globus’s expansion into an area beyond its focus on musculoskeletal technologies, where it describes itself as a leader. The company is placing the new technologies within its portfolio of tools that support neurosurgery. The statement did not specify Synaptive’s business size or its financial impact on Globus.
Globus said its immediate priority is to ensure continuity of service for Synaptive customers. The company has begun contacting customers and stakeholders and is working to establish support services for the installed base. At the same time, it is still developing the long-term commercial strategy for the acquired business. The prioritization makes operating support services an immediate step, while the broader commercialization plan remains in development. The company did not give a timeline for completing the plan or details of its business model in the announcement.
On further development, Globus said the acquisition creates opportunities to build integrated procedural solutions that bring together imaging, navigation and surgical planning with its Excelsius platform. The company framed this as development opportunities, without announcing a ready integrated product or a launch timeline. This path could connect Synaptive’s tools with the enabling technology ecosystem Globus is developing, while the final scope of commercial and technical integration remains undisclosed. It is also tied to the company’s stated goal of deepening its presence in cranial neurosurgery. The statement did not estimate the expected returns from this integration.
The deal follows Synaptive’s entry into receivership proceedings in Ontario. On April 28, 2026, the Ontario Superior Court appointed Richter as receiver and manager of all Synaptive’s assets, undertakings and property. The acquisition was subsequently completed through those proceedings, Globus said. Before the announcement, the company reported net sales of about $789.6 million in the second quarter of 2026, up 5.9% from the same period in 2025, while international sales rose 18.0% on a reported basis year over year. Keith Pfeil said growth benefited from market-share gains across most core businesses, with U.S. spine sales up 7% and international sales up 14% on a reported basis.
Globus had scheduled its third-quarter 2026 results announcement for after the market close on November 5, with the earnings call set to begin at 4:30 p.m. Eastern time. The results were therefore still pending when the acquisition completion was announced on November 3. The deal statement provided no figures on Synaptive’s impact on third-quarter results or its future financial contribution. The next announced steps center on customer support and completing the long-term commercial strategy. The company also gave no date for further details on integrating Synaptive’s technologies with the Excelsius platform.